These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35284802)

  • 21. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Ryan CE; Brander DM; Barr PM; Tyekucheva S; Hackett LR; Collins MC; Fernandes SM; Ren Y; Zhou Y; McDonough MM; Walker HA; McEwan MR; Abramson JS; Jacobsen ED; LaCasce AS; Fisher DC; Brown JR; Davids MS
    Leukemia; 2023 Apr; 37(4):835-842. PubMed ID: 36717653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
    Bravo J; Baltasar Tello P; González Garcia E; Ríos Herranz E; Páyer AR; Terol Castera MJ; Champ D; Medina Perez A; Gironella M; Fernández Zarzoso M; Forés R; Delgado J; Garcia-Marco JA;
    Leuk Lymphoma; 2023 May; 64(5):913-926. PubMed ID: 37255002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
    Sharman J; Hawkins M; Kolibaba K; Boxer M; Klein L; Wu M; Hu J; Abella S; Yasenchak C
    Blood; 2015 Apr; 125(15):2336-43. PubMed ID: 25696919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab.
    Smolej L
    Pharmgenomics Pers Med; 2015; 8():1-7. PubMed ID: 25691812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.
    Qin Y; Song Y; Shen Z; Du X; Ji W; Hsu W; Zhu J; Shi Y
    Cancer Commun (Lond); 2018 May; 38(1):31. PubMed ID: 29843792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
    Cartron G; de Guibert S; Dilhuydy MS; Morschhauser F; Leblond V; Dupuis J; Mahe B; Bouabdallah R; Lei G; Wenger M; Wassner-Fritsch E; Hallek M
    Blood; 2014 Oct; 124(14):2196-202. PubMed ID: 25143487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
    Kakkar AK; Balakrishnan S
    J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
    Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
    Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Novak J; Strugov V; Gill D; Gribben JG; Kwei K; Dai S; Hsu E; Dean JP; Flinn IW
    Haematologica; 2022 Sep; 107(9):2108-2120. PubMed ID: 35021599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
    Awan FT; Thirman MJ; Patel-Donnelly D; Assouline S; Rao AV; Ye W; Hill B; Sharman JP
    Leuk Lymphoma; 2019 Aug; 60(8):1972-1977. PubMed ID: 30633573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
    Said R; Tsimberidou AM
    Expert Opin Biol Ther; 2017 Nov; 17(11):1463-1470. PubMed ID: 28893099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
    Goede V; Klein C; Stilgenbauer S
    Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
    Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
    Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
    Kater AP; Owen C; Moreno C; Follows G; Munir T; Levin MD; Benjamini O; Janssens A; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Ysebaert L; Qin R; Steele AJ; Schuier N; Baeten K; Caces DB; Niemann CU
    NEJM Evid; 2022 Jul; 1(7):EVIDoa2200006. PubMed ID: 38319255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective.
    Owen CJ; Stewart DA
    Ther Adv Hematol; 2015 Aug; 6(4):161-70. PubMed ID: 26288711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
    Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
    Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
    Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Salvaris R; Opat S
    Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab.
    Shah A
    Ther Clin Risk Manag; 2015; 11():1113-22. PubMed ID: 26251607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.